Use of human AURKB gene in the preparation of anti-tumor drugs
By constructing shRNA and lentiviral vectors of the AURKB gene, inhibiting AURKB gene expression, the problem of lack of effective antiesophageal cancer drugs in the prior art is solved, efficient inhibition and apoptosis promotion of tumor cells is achieved, and new tumor treatment is provided method.
Patent Information
- Application Number
- CN202211624072.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2022-12-16
- Publication Date
- 2024-11-05
- Estimated Expiration
- 2042-12-16
AI Technical Summary
There is a lack of effective anti-esophageal cancer drugs in the prior art, especially the use of the AURKB gene in the preparation of anti-tumor drugs, which has not been reported, resulting in difficulty in diagnosis and treatment of advanced esophageal cancer and high mortality rate.
By constructing small molecule interfering RNA and interfering nucleic acid constructs of the human AURKB gene, the shRNA sequence is transformed into the target cell using lentiviral vectors, inhibiting the expression of AURKB gene, thereby inhibiting the growth of tumor cells and promoting apoptosis.
The specific inhibition of the AURKB gene was achieved, efficiently inhibited the growth and proliferation of tumor cells, promoted apoptosis, and provided new tumor treatment strategies, especially effective means for esophageal cancer.
Smart Images

Figure CN116173059B_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the field of biotechnology, and specifically relates to the use of human AURKB gene in preparing anti-tumor drugs. Background Art
[0002] Esophageal cancer, including esophageal adenocarcinoma (EAC) and esophageal squamous cell carcinoma (ESCC), is a malignant tumor that seriously threatens human health. Esophageal cancer is the seventh most common cancer in the world, and ESCC accounts for more than 90% of esophageal cancer. Due to the lack of effective diagnosis and treatment strategies, esophageal cancer diagnosed in the late stage has a high mortality rate.
[0003] Aurora kinases (AURKs) are protein serine / threonine kinases consisting of three members in the gene family - Aurora kinase A (AURKA), Aurora kinase B (AURKB) and Aurora kinase C (AURKC). AURKA is mainly involved in centrosome maturation, separation and bipolar spindle assembly, while AURKC is mainly involved in chromosome assembly during mitosis in mammalian cells. AURKB, also known as AIM-1 or Stk-5, forms a chromosome-binding complex (CPC) with inner centromere protein (INCENP), Survivin, Borealin / Dasra and other proteins.
[0004] Currently, there is no report on the use of AURKB gene in the preparation of anti-esophageal cancer drugs. Summary of the invention
[0005] The purpose of the present invention is to provide the use of human AURKB gene in the preparation of anti-tumor drugs.
[0006] In order to solve the above technical problems, the technical solution adopted by the present invention is:
[0007] Use of shRNA that inhibits human AURKB gene in the preparation of anti-tumor drugs.
[0008] Use of shRNA that inhibits human AURKB gene in preparing anti-esophageal cancer drugs.
[0009] In the above uses, the shRNA sequence is:
[0010] ShRNA1-F: 5'-GATCC GGAGGAGGATCTACTTGATTC TTCAAGAGAGAATCAAGTAGATCCTCCTCC TTTTTG-3';
[0011] ShRNA1-R: 5'-AATTCAAAAA GGAGGATCTACTTGATTC TCCTCTTGAAGAATCAAGTAGATCCTCCTCC G-3';
[0012] or
[0013] ShRNA2-F: 5'-GATCC GCAGAAGAGCTGCACATTTGA TTCAAGAGATCAAATGTGCAGCTCTTCTGC TTTTTG-3';
[0014] ShRNA2-R: 5'-AATTCAAAAA GCAGAAGAGCTGCACATTTGATCTCTTGAATCAAATGTGCAGCTCTTCTGC G-3';
[0015] or
[0016] ShRNA3-F: 5'-GATCC GCATTGGAGTGCTTTGCTATG TTCAAGAGACATAGCAAAGCACTCCAATGC TTTTTG-3';
[0017] ShRNA3-R: 5'-AATTCAAAAA GCATTGGAGTGCTTTGCTATG TCTCTTGAACATAGCAAAGCACTCCAATGC G-3'.
[0018] The present invention also relates to a method for preparing an anti-esophageal cancer drug, comprising the following steps: retrieving a human AURKB gene sequence from Genbank; predicting multiple shRNA target sites;
[0019] Screening shRNA targets, adding a loop sequence to the selected shRNA target sequence to obtain an effective shRNA sequence for the AURKB gene;
[0020] According to the shRNA sequence, a double-stranded DNA oligonucleotide sequence with restriction sites at both ends was designed and synthesized;
[0021] The lentiviral vector was double-digested and ligated with a double-stranded DNA oligonucleotide sequence to construct an RNAi shuttle plasmid expressing the AURKB gene shRNA sequence;
[0022] Transform the RNAi shuttle plasmid into competent cells for cloning;
[0023] The RNAi shuttle plasmid and the auxiliary vector required for lentiviral packaging were co-transfected into human embryonic kidney 293T cells to produce recombinant lentiviral particles.
[0024] In the above method for preparing the anti-esophageal cancer drug, the lentiviral vector is selected from pLVX-shRNA2-Puro.
[0025] The beneficial effects of the present invention are as follows: the present invention constructs a human AURKB gene small molecule interfering RNA, a human AURKB gene interfering nucleic acid construct, and a human AURKB gene interfering lentivirus and discloses their use in preparing anti-tumor drugs. The present invention provides shRNA or a nucleic acid construct or lentivirus containing the shRNA sequence, which can specifically inhibit the expression of human genes, especially lentivirus, which can efficiently infect target cells, efficiently inhibit the expression of genes in target cells, thereby inhibiting the growth of tumor cells and promoting tumor cell apoptosis, and has important significance in tumor treatment. BRIEF DESCRIPTION OF THE DRAWINGS
[0026] Figure 1 This is a graph showing the changes in AURKB expression levels in human esophageal cancer cell KYSE-150 under infection with the prepared lentivirus;
[0027] Figure 2 This is a graph showing the changes in AURKB expression levels in human esophageal cancer cell TE-1 under infection with the prepared lentivirus;
[0028] Figure 3 This is a graph showing changes in the cell proliferation ability of human esophageal cancer cell KYSE-150 under infection with the prepared lentivirus;
[0029] Figure 4 This is a graph showing changes in the cell proliferation ability of human esophageal cancer cell TE-1 under infection with the prepared lentivirus;
[0030] Figure 5 This is a graph showing changes in apoptosis levels of human esophageal cancer cell KYSE-150 under infection with the prepared lentivirus;
[0031] Figure 6 This is a graph showing changes in apoptosis levels in human esophageal cancer cell TE-1 under infection with the prepared lentivirus. DETAILED DESCRIPTION
[0032] In order to explain the technical content, achieved objectives and effects of the present invention in detail, the following is an explanation in combination with the implementation modes and the accompanying drawings.
[0033] Studies have shown that CPC plays a central role in mitosis, mediating the correction of chromosome-microtubule attachment errors, activation of spindle assembly, and regulation of chromosome segregation and cell division. AURKB is localized at the centromere and is mainly involved in the transition of cell division from G2 to M phase during the transition from prophase to metaphase-end phase. Previous studies have shown that AURKB can phosphorylate histone H3 on serine 10 (H3S10) and serine 28 (H3S28), which is related to chromosome number stability and chromatin condensation during mitosis.
[0034] RNA interference (RNAi) is a natural process that specifically degrades mRNA in cells mediated by double-stranded RNA, thereby inhibiting or silencing the expression of target genes. RNAi technology mainly includes small interfering RNA (siRNA), short hairpin RNA (shRNA) and bi-functional shRNA. shRNA consists of two complementary 19-22bp RNA sequences and a 4-11nt stem-loop. The function of the stem-loop structure is to separate the two sequences. shRNA can integrate into the genome. After transcription, shRNA is exported to the cytoplasm and recognized by the endogenous enzyme Dicer. shRNA is processed into double-stranded siRNA, which then binds to the target gene mRNAs and merges with the RNA-induced silencing complex, thereby degrading the target gene mRNAs to exert the RNA interference effect.
[0035] Lentiviral vectors have become one of the most widely used vectors in basic biology, functional genomics and gene therapy. Compared with other retroviruses, the advantages of lentiviruses are obvious. Lentiviruses have a relatively wide range of hosts and are able to infect both dividing and non-dividing cells. They also have the advantages of a short production cycle, high infection efficiency and high exogenous gene integration efficiency, and are an efficient method for introducing exogenous genes.
[0036] In the present invention, the lentivirus vector transduces the AURKB gene into KYSE150 and TE-1 cells, inserts it into the genome of the cells and stably expresses it, and obtains cell clones that inhibit the expression of the AURKB gene through puromycin screening. The cell clones are further cultured and passaged to form stable cell lines that inhibit the expression of AURKB.
[0037] The present invention discloses the use of human AURKB gene and related drugs. The present invention discloses new uses of human AURKB gene in tumor treatment, tumor diagnosis and drug preparation. The present invention further constructs human AURKB gene small molecule interfering RNA, human AURKB gene interfering nucleic acid construct, human AURKB gene interfering lentivirus and discloses their uses. The shRNA or nucleic acid construct and lentivirus containing the shRNA sequence provided by the present invention can specifically inhibit the expression of human AURKB gene, especially the lentivirus, which can efficiently infect target cells, efficiently inhibit the expression of AURKB gene in target cells, thereby inhibiting the growth of tumor cells and promoting tumor cell apoptosis, which is of great significance in tumor treatment.
[0038] The present invention uses RNA interference as a means to study the role of AURKB gene in tumor occurrence and development, and discloses a method for inhibiting or reducing tumor cell growth, proliferation, differentiation and / or survival, the method comprising: administering a molecule that can specifically inhibit the transcription or translation of AURKB gene, or can specifically inhibit the expression or activity of AURKB protein to tumor cells, thereby inhibiting the growth, proliferation, differentiation and / or survival of tumor cells. The tumor cells are selected from any one of esophageal cancer.
[0039] Example 1
[0040] The method for preparing an antitumor drug comprises the following steps:
[0041] Step 1: retrieve the human AURKB gene sequence from Genbank; predict multiple shRNA targets;
[0042] Specifically, the base sequence of human AURKB (NM_004217.4) was searched in the National Center for Biological Information (NCBI) of the United States, and the BLOCK-iT TM RNAi Designer software designed 10 pairs of effective shRNA targets for the coding sequence region, as shown in Table 1:
[0043] Table 1
[0044]
[0045] Step 2: Screening shRNA targets, adding a loop sequence, TTTTT+restriction site, etc. to the selected shRNA target sequence to obtain an effective shRNA sequence for the AURKB gene;
[0046] Step 3: Based on the shRNA sequence, design and synthesize a double-stranded DNA oligonucleotide sequence with restriction sites at both ends;
[0047] Specifically, three sequences with the largest Rank scores (NO.2, NO.5, NO.9) were selected from Table 1, TTCAAGAGA (circular sequence), TTTTT+restriction site were added, and complementary antisense oligonucleotide chains were designed, and double-stranded DNA oligonucleotide sequences containing restriction sites at both ends were annealed and synthesized, as shown in Table 2;
[0048] Table 2
[0049]
[0050]
[0051] The synthesis of a double-stranded DNA oligonucleotide sequence containing restriction sites at both ends includes annealing the upstream and downstream fragments of the single-stranded shRNA to form a double-stranded DNA fragment.
[0052] The annealing reaction system is shown in Table 3:
[0053] Table 3
[0054]
[0055] Annealing reaction procedure: 95°C, 5 min; cooling at room temperature for 1-2 h.
[0056] Step 4: After double restriction digestion, the lentiviral vector was connected with the double-stranded DNA oligonucleotide sequence to construct an RNAi shuttle plasmid expressing the AURKB gene shRNA sequence;
[0057] Specifically, the lentiviral vector is selected from the pLVX-shRNA2-Puro vector, and the enzyme digestion system of the pLVX-shRNA2-Puro vector is shown in Table 4:
[0058] Table 4
[0059]
[0060]
[0061] pLVX-shRNA2-Puro vector digestion conditions: 37°C, 2-3h; identified by agarose gel, and recovered by gel excision;
[0062] The pLVX-shRNA2-Puro vector is connected to the above double-stranded DNA oligonucleotide sequence through the restriction site. Since the shRNA fragment has sticky ends after restriction digestion, it can be directly connected to the vector after restriction digestion.
[0063] The vector and gene connection system after enzyme digestion are shown in Table 5.
[0064] Table 5
[0065]
[0066] Step 5: Transform the RNAi shuttle plasmid into competent cells for cloning;
[0067] Specifically, the ligated recombinant plasmid was transformed into E. coli competent cells Stbl3.
[0068] The specific operations are as follows:
[0069] 1) Take out the competent cells Stbl3 (100 μL) from the -80°C freezer, quickly put it on ice, let it stand for 5 min to thaw, and divide it into 2 tubes, each containing 50 μL;
[0070] 2) Add 1 μL of recombinant plasmid (the volume of DNA solution should not exceed 5% of the volume of competent cells, 1 ng of cccDNA can saturate 50 μL of competent cells), shake gently to mix, and then place on ice for 30 minutes;
[0071] 3) Place the mixture in a 42°C water bath for 90 seconds for heat shock, quickly transfer to ice, and start timing for 3 minutes;
[0072] 4) Add 900 μL of LB liquid medium without resistance, set the constant temperature shaker temperature to 37°C, the speed to 200 r / min, and culture for 1 h;
[0073] 5) Take 5 culture dishes with solid LB-AMP, take 100 μL of the suspended bacterial solution and spread it evenly with a glass coating rod burned by an alcohol lamp, and invert and culture in a constant temperature incubator at 37°C for 15 hours, 40 μL;
[0074] 6) Pick a single colony and inoculate it into 15 mL (small extract) of LB liquid medium containing ampicillin resistance, set the temperature of the constant temperature shaker to 37°C, the speed to 180 r / min, and culture overnight;
[0075] 7) Bacterial liquid sequencing: Sequencing results were compared using DNAMAN.
[0076] 8) Plasmid extraction: Transfer the correctly sequenced bacterial solution into 10 ml LB liquid culture medium containing corresponding antibiotics, culture at 37°C overnight, and use Tiangen Endotoxin-Free Plasmid Extraction Kit for plasmid extraction. The qualified plasmids will enter the downstream process.
[0077] Step 6: Co-transfect the RNAi shuttle plasmid and the auxiliary vector required for lentiviral packaging into human embryonic kidney 293T cells to produce recombinant lentiviral particles.
[0078] Specifically, the AURKB-shRNA interference lentiviral packaging procedure is as follows:
[0079] 293T cells were seeded in a 10cm-dish, and the seeding density was about 80% of the cell density before transfection on the second day, and cultured in a 37°C, 5% CO2 incubator. The third-generation lentiviral packaging system (auxiliary plasmids: MDLg / pRRE, pRSV-Rev, pMD2.G) was used for lentiviral packaging. The following plasmid mixture was added to the 293T cell culture dish according to the instructions of Lipofectamine3000, and the cell supernatant containing lentivirus was collected at 48 hours and 72 hours respectively. The plasmid co-transfection system is shown in Table 6:
[0080] Table 6
[0081]
[0082] The cell supernatant collected twice was mixed and centrifuged at 4°C and 3000g for 25 minutes to precipitate the cell debris, and the supernatant was filtered through a 0.45μm microporous filter into an ultracentrifuge tube and centrifuged at 100000g for 120 minutes. The supernatant was discarded, and the virus at the bottom of the tube was fully dissolved with 1ml PBS solution, and the pipette tip was blown several times, and the aliquots were quickly placed in a -80°C refrigerator for long-term storage, which was used for the preparation of anti-tumor drugs, especially for the preparation of anti-esophageal cancer drugs.
[0083] Experimental Example 1
[0084] Q-PCR was used to detect the AURKB gene interference efficiency in human esophageal cancer cells;
[0085] Establishment of stable low-expression cell lines: KYSE-150 and TE-1 human esophageal cancer cells were inoculated in 6-well plates. When the cell density reached 60%, the formal infection experiment was carried out using the lentiviral infection MOI and optimal infection conditions determined in the preliminary experiment. After 3-4 days of cell infection, the total RNA of the cells was extracted using the NucleoZol reagent, and 1 μg of RNA was reverse transcribed into cDNA using the Promega reverse transcription kit. The relative expression of AURKB was detected according to the qPCR MasterMix manual, and β-actin was used as an internal reference to screen the stable interfering cell lines. AURKB primers are as follows: upstream primer: 5'-GTGCATCACACAACGAGACC-3', downstream primer: 5'-GCCTGAGCAGTTTGGAGATG-3'; β-actin primers: upstream primer: 5'-TGACGTGGACATCCGCAAAG-3', downstream primer: 5'-CTGGAAGGTGGACAGCGAGG-3'. The data were analyzed by relative quantitative analysis according to the 2-ΔΔCt method, and the calculation formula is as follows (x represents any sample): ΔΔCt=(C t.Target –C t.β-actin )X–(C t.Target –C t.β-actin ) Control .
[0086] The reverse transcription systems involved above are as follows:
[0087] The first stage: denaturing and melting the total RNA; the system is shown in Table 7:
[0088] Table 7
[0089]
[0090] Add reagents as written above, mix by microcentrifugation for 10 seconds, bathe at 70°C for 5 minutes, and then immediately bathe on ice for 5 minutes;
[0091] The second stage: reverse transcription reaction; the system is shown in Table 8;
[0092] Table 8
[0093]
[0094]
[0095] Add reagents as described above, mix by microcentrifugation for 10 seconds, incubate at 25°C for 5 minutes, 42°C for 60 minutes, and 70°C for 15 minutes.
[0096] The real-time PCR reaction system is shown in Table 9;
[0097] Table 9
[0098]
[0099] The qPCR program settings are shown in Table 10;
[0100] Table 10
[0101]
[0102] Reference Figure 1 as well as Figure 2 ,The experimental results showed that compared with the negative interference group, the expression levels of AURKB in KYSE-150 and TE-1 human esophageal cancer cells were downregulated, ,respectively.
[0103] Experimental Example 2
[0104] The proliferation of human esophageal cancer cells in the control group and sh-AURKB interference group was detected by CCK-8 method;
[0105] Different groups of KYSE-150 and TE-1 human esophageal cancer cells were cultured for 24 h and then harvested by trypsinization. 4 Cells were inoculated into a 96-well plate at a concentration of 10 cells / ml, and 10 μL of 10% CCK-8 solution was added to each well at 24, 48, 72, and 96 hours, and cultured for 2 hours. The absorbance of each well was detected at OD450 nm using an enzyme-linked immunosorbent assay.
[0106] Reference Figure 3 as well as Figure 4 The experimental results showed that compared with the control group, the proliferation ability of KYSE-150 and TE-1 human esophageal cancer cells in the interference group was weakened.
[0107] Experimental Example 3
[0108] Flow cytometry was used to detect the apoptosis of human esophageal cancer cells in the control group and sh-AURKB interference group;
[0109] The KYSE-150 and TE-1 human esophageal cancer cells of different groups were collected after trypsin digestion, washed twice with 4°C precooled PBS, and resuspended with 250 μL binding buffer to adjust the concentration to 1×10 6 / ml; take 100μL of cell suspension in a 5ml flow tube, add 5μL AnnexinV / Alexa Fluor 647 and 10μL 20μg / ml propidium iodide solution. After mixing, incubate at room temperature in the dark for 15 minutes, add 400μl PBS to the reaction tube, and detect the apoptosis of SGC-7901 cells by flow cytometry (FACS).
[0110] Reference Figures 5 and 6 The experimental results showed that the apoptosis levels of KYSE-150 and TE-1 human esophageal cancer cells in the interference group were significantly higher than those in the control group.
[0111] The above descriptions are merely embodiments of the present invention and are not intended to limit the patent scope of the present invention. Any equivalent transformations made using the contents of the present invention's specification and drawings, or directly or indirectly applied in related technical fields, are also included in the patent protection scope of the present invention.
Claims
1. Use of shRNA that inhibits human AURKB gene in the preparation of drugs that inhibit KYSE-150 and TE-1 cells, wherein the shRNA sequence is: ShRNA3-F: 5'-GATCC GCATTGGAGTGCTTTGCTATG TTCAAGAGA CATAGCAAAGCACTCCAATGCTTTTTG-3'; ShRNA3-R: 5'-AATTCAAAAA GCATTGGAGTGCTTTGCTATG TCTCTTGAACATAGCAAAGCACTCCAATGC G-3'.
2. The method for preparing the drug for inhibiting KYSE-150 and TE-1 cells according to claim 1, characterized in that: The method comprises the following steps: retrieving the human AURKB gene sequence from Genbank; predicting multiple shRNA target sites; Screening shRNA targets, adding a loop sequence to the selected shRNA target sequence to obtain an effective shRNA sequence targeting the AURKB gene; According to the shRNA sequence, a double-stranded DNA oligonucleotide sequence with restriction sites at both ends was designed and synthesized; The lentiviral vector was double-digested and ligated with a double-stranded DNA oligonucleotide sequence to construct an RNAi shuttle plasmid expressing the shRNA sequence of the AURKB gene; Transform the RNAi shuttle plasmid into competent cells for cloning; The RNAi shuttle plasmid and the auxiliary vector required for lentiviral packaging were co-transfected into human embryonic kidney 293T cells to produce recombinant lentiviral particles.
3. The method for preparing a drug for inhibiting KYSE-150 and TE-1 cells according to claim 2, characterized in that: The lentiviral vector is selected from pLVX-shRNA2-Puro.
